Log in to save to my catalogue

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersec...

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersec...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b1804735a385439d93d084143b971507

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

About this item

Full title

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

Publisher

England: BioMed Central Ltd

Journal title

Respiratory research, 2020-06, Vol.21 (1), p.149-149, Article 149

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

Oral CXC chemokine receptor 2 (CXCR2) antagonists have been shown to inhibit neutrophil migration and activation in the lung in preclinical and human models of neutrophilic airway inflammation. A previous study with danirixin, a reversible CXCR2 antagonist, demonstrated a trend for improved respiratory symptoms and health status in patients with CO...

Alternative Titles

Full title

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_b1804735a385439d93d084143b971507

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_b1804735a385439d93d084143b971507

Other Identifiers

ISSN

1465-993X,1465-9921

E-ISSN

1465-993X,1465-9921

DOI

10.1186/s12931-020-01401-4

How to access this item